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Abstract
Background: According to established ethical principles and guidelines, patients in clinical trials should be fully informed
about the interventions they might receive. However, information about placebo-controlled clinical trials typically focuses on the
new intervention being tested and provides limited and at times misleading information about placebos.
Objective: We aimed to create an informative, scientifically accurate, and engaging website that could be used to improve
understanding of placebo effects among patients who might be considering taking part in a placebo-controlled clinical trial.
Methods: Our approach drew on evidence-, theory-, and person-based intervention development. We used existing evidence
and theory about placebo effects to develop content that was scientifically accurate. We used existing evidence and theory of
health behavior to ensure our content would be communicated persuasively, to an audience who might currently be ignorant or
misinformed about placebo effects. A qualitative ‘think aloud’ study was conducted in which 10 participants viewed prototypes
of the website and spoke their thoughts out loud in the presence of a researcher.
Results: The website provides information about 10 key topics and uses text, evidence summaries, quizzes, audio clips of
patients’ stories, and a short film to convey key messages. Comments from participants in the think aloud study highlighted
occasional misunderstandings and off-putting/confusing features. These were addressed by modifying elements of content, style,
and navigation to improve participants’ experiences of using the website.
Conclusions: We have developed an evidence-based website that incorporates theory-based techniques to inform members of
the public about placebos and placebo effects. Qualitative research ensured our website was engaging and convincing for our
target audience who might not perceive a need to learn about placebo effects. Before using the website in clinical trials, it is
necessary to test its effects on key outcomes including patients’ knowledge and capacity for making informed choices about
placebos.
(JMIR Res Protoc 2016;5(2):e106)  doi: 10.2196/resprot.5627
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Introduction
Clinical trials must be conducted in accordance with Good
Clinical Practice guidelines [1] and ethical principles espoused
in the Declaration of Helsinki [2]. In particular, patients should
be fully informed about the interventions they might receive
and must give written informed consent. In a placebo-controlled
randomized clinical trial this means that all participants should
be fully informed about both the new intervention being tested
and the placebo control. However, a content analysis of
participant information leaflets from United Kingdom–based
placebo-controlled trials found that written information about
placebos is typically incomplete and at times misleading [3].
For example, despite strong evidence of placebo effects and
mechanisms in the scientific literature, [4-7] only 1 of 45 leaflets
explicitly stated that patients might experience beneficial effects
from the placebo [3]. Using placebos in clinical trials appears
to be generally acceptable to patients, but crucially this depends
not only on the severity of the condition being treated and
available alternative controls, but also the adequacy of informed
consent [8]. Furthermore, evidence from surveys and qualitative
studies shows that clinical trial participants often have false
beliefs about, and partial understanding of, placebos and their
possible effects [9-11]. Examples of such false beliefs include
the belief that placebo effects are fake, or illusory, and that
people who respond to placebos are gullible or foolish [11-13].
This might explain why the inclusion of placebo controls can
deter people from volunteering to participate in trials [14].
Overall, it seems that a significant proportion of clinical trial
participants might have inadequate understandings of the
potential clinical effects of placebo interventions [9-13], thus
jeopardizing the ethical validity of informed consent [3] and
potentially hampering recruitment [14]. More accurate and
complete information about placebos could usefully address
this ethical shortcoming, could combat patient anxiety about
placebo effects [12], and reduce distress at being debriefed in
placebo condition participants [15,16].
This paper describes the development of an educational website
about placebo effects. We aimed to create an informative,
scientifically accurate, and engaging website that could be used
to improve understanding of placebo effects among patients
who might be considering taking part in a placebo-controlled
clinical trial. We chose to develop a website rather than a
traditional printed information leaflet because websites (1) are
increasingly popular sources of consumer health [17-20],
suggesting that this format reflects consumer preferences, (2)
easily incorporate interactive features [21], which can enhance
engagement and effective education[22], (3) are easily and
cheaply disseminated for widespread access [21] (86% of UK
households had Internet access and 78% of adults accessed the
Internet daily or almost daily in 2015 [23]), and (4) can be
readily adapted and/or tailored to different subgroups [21]. Our
intention was to develop a resource that could potentially be
used across a large number of clinical trials and/or adapted for
use in specific trials. However, because the effects and
mechanisms of placebos differ across symptoms and diseases
[24], we chose one clinical target to focus on for this version
of the website. We chose placebo analgesia as pain is relevant
to a large number of clinical conditions and placebo analgesia
is a well-documented placebo effect [4,25-27]. The target
audience for this website was thus adults experiencing pain
symptoms (from any clinical condition).
Methods
An Evidence-, Theory-, and Person-Based Approach
We drew on existing evidence and theory, and conducted
qualitative research to develop our website using an approach
derived from evidence-based, theory-based [28,29], and
incorporating elements of person-based [30] intervention
development. In the context of a website about placebos, we
felt this combined approach was more valuable than any single
approach. It was important to use existing evidence and theory
about placebo effects to ensure our content was scientifically
accurate. Drawing on existing evidence and theory about health
behavior was essential to ensure our content would be
communicated persuasively to an audience who might currently
be ignorant or misinformed about placebo effects. Conducting
our own qualitative research was necessary to ensure our website
was engaging and convincing for our target audience who might
not have a perceived need to learn about placebo effects. Figure
1 provides an overview of the process of developing the website.
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Figure 1. Overview of methods used to develop the website.
Planning the Intervention
To plan the content and structure of the website we considered
four key questions:
What psychological targets are relevant to providing information
about placebos? In other words, what would we expect to change
as a result of viewing our website?
What do patients typically believe about placebos and placebo
effects?
What is the current scientific understanding of placebos and
placebo effects?
How should information about placebos and placebo effects be
provided to be most effective?
Psychological Targets
Given current partial understandings, misunderstandings, and
poor quality information about placebos [3,9-11], we decided
our website should focus on promoting informed choices about
placebos. Making an informed choice can be understood as
choosing to act in a way that is based on one’s knowledge and
one’s values [31-33]. According to this definition, it is incorrect
to specify that a particular option is the correct choice for
everyone: what counts as the informed choice will differ across
equally knowledgeable individuals according to their values.
To make an informed choice, a person needs to have an accurate
understanding of the options available, have formed an opinion
about the options based on their values, and make a decision
(or otherwise act in a way) that is consistent with their
knowledge and values. We chose to focus on informed choice,
rather than informed consent, because the process of informed
consent to take part in a placebo-controlled clinical trial would
typically involve a face-to-face interaction between trial
personnel and potential participants and would involve the
provision of trial-specific information (eg, about the trial
intervention). Our website is intended to provide a generic
resource to educate and inform members of the public who may
be considering receiving placebos as part of a clinical trial.
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In the context of placebos, an informed choice to receive a
placebo (eg, by taking part in a trial) requires knowledge about
the possible effects of placebos, a positive attitude to taking
placebos, and a decision to take placebos. An informed choice
not to receive a placebo requires knowledge about the possible
effects of placebos, a negative attitude to taking placebos, and
a decision not to take placebos. To promote informed choice
our website thus needed to improve people’s knowledge of
placebos. Therefore, knowledge about placebos and their effects
was our primary target for change.
Making an informed choice to receive placebos can be
understood as a volitional behavior, and thus can be modelled
using the Theory of Planned Behavior [34]. According to the
Theory of Planned Behavior, patients’ intentions to take
placebos are driven by attitudes, subjective norms, and perceived
behavioral control. These, in turn, are determined by beliefs
[34]. Thus, patients will be more likely to make an informed
choice to receive placebos if they (1) believe that placebos are
effective/good for them and value these effects (attitudes), (2)
believe that people whose opinion they value would approve
of placebos (subjective norms), and (3) believe that they control
whether or not they receive placebos (perceived behavioral
control). While we did not want to encourage people to decide
to receive placebos (except in the context of an informed
choice), we did want to provide information that was consistent
with people’s existing cognitive structures. Therefore, we
designed the website to address the following: consequences
of receiving placebos for the individual (attitudes), other
people’s views on placebos (subjective norms), and practicalities
around receiving placebos (perceived behavioral control).
Typical Beliefs About Placebos
To understand typical beliefs about placebos we reviewed
qualitative studies of patients’ experiences of placebos in clinical
trials. This literature showed that people are interested in but
often anxious about or confused by placebos [35,36]. For
example, in qualitative studies embedded in acupuncture trials
patients described interest or anxiety as to whether they receive
placebo or real treatment [37], and the knowledge that they may
receive placebo made them doubt any perceived improvements
in symptoms [12,13]. Patients conceptualize placebos and their
effects in various ways, dominant among which are
understandings of placebos: as fake treatments that fool people
into thinking they are better; as tools that are necessary for
scientific research; and as interventions that have real effects
mediated by psychological mechanisms [11]. Patients’ reactions
to being told they had been in the placebo arm of one clinical
trial included surprise and disbelief. Some worried that they
would ‘throw the trial off’ and interpreted their experiences in
a way that affirmed their understanding of their illness or
emphasized the positive effect of social support from trial staff
[15].
Based on these findings, we devised website content to describe
the possible (positive and negative) effects and experiences of
placebo (‘can it help?’, ‘what is it like?’). The website also
addresses common concerns about placebos (‘what concerns
me’), debunks myths that placebo responders are malingerers
or gullible (‘who does it help?’), and explains the mechanisms
underpinning placebo effects (‘how could it work?’).
Scientific Understanding of Placebo Effects
To ensure scientific accuracy we consulted systematic and
narrative reviews and seminal studies concerning the effects
and mechanisms of action of placebos [4,6,7,24]. We selected
key evidence-based facts about placebo effects to convey in the
website including: placebos can relieve pain and stiffness in
osteoarthritis [27]; placebos can improve reported pain across
a number of painful conditions [25]; and placebos can elicit
side effects in what is called a ‘nocebo’ effect [38] (ie, the
negative aspect of the placebo effect that occurs when an adverse
event, such as experiencing side effects, is triggered by negative
expectations [39]). The website also conveyed that it is difficult
to know how many people placebos will work for, but they
seem to improve pain for between 26% and 51% of people in
placebo studies [6].
The mechanisms of action of placebos have been described in
neurobiological, psychological, and anthropological terms.
Patients also appear to develop understandings of placebo effects
at different levels, with some focusing on psychological
processes and others emphasizing social processes [11,15]. To
accurately represent the scientific literature and appeal to
different patients, we therefore chose to convey a number of
different theories of placebo effects, specifically neurobiological
pathways [40], expectancy [41], conditioning [42], meaning
response [43], and the therapeutic relationship [44].
We also drew on scientific literature when developing material
on other aspects of placebos outlined in the previous section.
For example, in addressing concerns that doctors have to lie to
patients to give them placebos, we drew on evidence about
open-label placebo prescribing, suggesting that doctors do not
have to lie to patients to elicit placebo effects [5].
Effective Information Provision
To plan how to provide information effectively to educate people
about placebos and thus improve their knowledge, we considered
a selection of relevant theories. In particular, we drew on
theories of motivation, learning, and attitude formation.
We drew on Self-Determination Theory [45] to plan how to
design our website so that it would be maximally engaging for
people. Self-Determination Theory distinguishes between
intrinsic motivation (eg, curiosity) and extrinsic motivation (eg,
payment) as drivers for action; our website relies on intrinsic
motivation as we do not anticipate eventual users to receive
external rewards for using it. Cognitive Evaluation Theory (1
of 6 ‘mini-theories’ within Self-Determination Theory)
elaborates on how social contexts can impact on intrinsic
motivation, and suggests that intrinsic motivation can be
enhanced by satisfying basic human needs of competence and
autonomy [45]. Thus, if the website supports people’s
perceptions of themselves as competent and autonomous it
should enhance intrinsic motivation and be more engaging. To
promote perceptions of competence, we designed easy quizzes
(using the word ‘surprise’ rather than ‘wrong’ to give feedback
on incorrect answers) and used simple and consistent navigation.
To promote perceptions of autonomy, we allowed users as much
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freedom of choice as possible, for example in terms of the order
in which to view different pages.
Educational theory suggests that people have different learning
styles [46]; therefore, we decided to provide information in
different formats: written text, photographs and images, audio
clips, and film. We used quizzes to engage readers in active
learning [47] and to test readers’ knowledge (tests are an
effective means of improving learning [48]). We also considered
to whom to attribute different sources of information. According
to Social Learning Theory, when we identify with another
person (a ‘model’) and perceive them to be competent and
similar to us, we may learn from observing them [49-51].
Therefore, we decided to use actors to narrate first-person
accounts of patients’ experiences of taking placebos, and to
choose actors of various ages, genders, and ethnicities. We drew
on qualitative studies of real patients’ experiences in clinical
trials to develop the first-person accounts [11-13,15].
While our focus was on educating people by providing accurate
information about placebos, attitude formation and change
processes might also occur in response to information provision.
According to leading theories of attitude change, there are both
central and peripheral routes to attitude formation and change
[52]. Central routes are well-described by the Elaboration
Likelihood Model and entail highly-motivated individuals
engaging in an effortful way with substantive messages,
assessing new information in relation to previously held beliefs,
and coming to a reasoned conclusion [53]. Peripheral routes,
as described by the Heuristic Systematic Model of persuasion,
entail the use of simple heuristics or ‘rules of thumb’ based on
superficial cues such as source credibility and number of
arguments presented [54,55]. To encourage the development
of more informed attitudes toward placebo effects, we described
scientific evidence to support our substantive message that
placebos can have effects, presented multiple scientific theories
about how placebos produce effects, and bolstered the credibility
of the message source by describing the website and study
authors’ academic credentials.
We followed guidance for developing patient-focused health
information by considering five key issues: information needs,
accessibility, quality, readability and comprehensibility, and
usefulness [56]. To ensure we addressed different needs for
information, we allowed readers a choice about whether to
access basic or more complex information. In other words, we
used simple text to convey basic information about a topic
(based on the literature), then offered a click-through to a more
detailed evidence summary describing a specific study or review,
and then offered another click-through to access the actual
scientific paper. To provide access to scientific evidence we
wrote accurate text, evidence summaries, and in some cases,
provided full papers. We considered color blindness and dyslexia
in our choice of colors and formatting; for example, using clear,
plain text and consistent formatting throughout. We also ordered
the items on the pages to make them more accessible for people
using text-reader software. To ensure we provided high-quality
information we used peer-reviewed publications and reviews.
To enhance readability we wrote in short sentences with simple
sentence construction and used readability indices to guide our
writing. To enhance usefulness, we provided information on
relevant topics (according to the literature on patients’ views
of placebos), included patient representatives in the research
team, and conducted a think aloud study to elicit users’
feedback.
Designing and Building the Intervention
We used the insights gained during the planning phase to write
the content and map out the initial structure of our website using
PowerPoint slides. Content was based on published evidence,
as described above. To ensure content was relevant to our
primary targets for change (knowledge, informed choice) and
mapped onto existing cognitive structures (attitudes, subjective
norms, perceived behavioral control), we reviewed each draft
page for relevance to these targets and structures. We then built
the website using LifeGuide open source software to facilitate
the design and scientific testing of Web-based behavior change
interventions [57].
Audio clips were produced for first-person narratives about the
phenomenology of placebo effects. A film was scripted and
produced to illustrate a placebo effect in an experimental context
(using a cold pressor task) and to describe the effects and
mechanisms of action of placebos. As a visual medium that
lends itself well to linear narrative, film provides an unrivalled,
vivid view of the world and may capture events, people, and
performances with detail and richness. Koumi [58] suggested
a number of considerations for writing instructional film scripts
including: the ‘hook’ (an element which captures viewers’
attention), asking questions, synergy between image and
narration, clarity of argument, audio/visual cues to denote
changes, and argument consolidation. The film we produced
integrated these steps through the use of animated infographic,
live action, interview, and narration to reinforce key messages.
While there is no hard-and-fast rule as to how many messages
a video can contain, studies show that people can store
approximately four discrete ‘chunks’ of information in
short-term memory [59], and some writers advise that a
30-minute video can comfortably elucidate three essential points
in some detail. As the placebo video has a running time of 4
minutes 20 seconds, the script was written to focus on two key
points: that placebos have significant, measurable, positive
effects on health, and that these effects are present in
conventional treatments.
Korakidou and Charitos [60] asserted that film involves viewers
on an emotional as well perceptual level, employing empathy
to facilitate engagement and retention. In addition, in
productions that include the spoken word it is believed that
viewers prefer and empathize more readily with conversational
language that is easily understood [61]. To facilitate this, the
video used live action sequences to encourage viewers to
imagine themselves in similar situations, and simple, jargon
free narration to ease comprehension and reduce cognitive load.
Think Aloud Study
A small qualitative study during this phase informed the final
content and structure of the website. Ethical approval was
obtained from the host institution (reference: ergo id 10933)
and all participants gave written informed consent. Posters and
Web-based advertisements were used to recruit 10 participants
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from the host institution (9 female, a mix of staff and students,
aged 19-35 years, 4 with musculoskeletal pain). They worked
through the website in the presence of the researcher, speaking
aloud their thoughts and answering specific, probing questions
(eg, “what do you think this page is about?”, “What did you
think about navigating through the site?”). The mean interview
duration was 32 minutes (range, 22-40) and interviews were
audio-recorded. Interviewees’ comments were reviewed and
coded according to the topic to which they referred using
deductively derived codes based on aspects of the website (eg,
“placebos in clinical practice”, “patients’ stories”) and
inductively derived codes for comments that did not relate
directly to specific contents (eg, “technical terms”). Comments
were further categorized as primarily related to content, style,
or navigation. Two researchers were involved in interpreting
interviewees’ comments, which avoided an idiosyncratic focus
on particular issues and enabled discussion of which comments
to prioritize when deciding on modifications to the website (eg,
in cases where interviewees provided divergent and/or
conflicting perspectives). Interviews proceeded iteratively, with
early interviews being analyzed first and used to inform changes
to the website that were then presented in later interviews.
Results
Comments from participants in the think aloud study highlighted
aspects of the website that participants felt were engaging as
well as occasional misunderstandings and stylistic and structural
features that were off-putting and/or confusing, and thus needed
improving. Elements of content, style, and navigation were
therefore modified to improve participants’ experiences of using
the website. Table 1 presents selected quotes from participants,
illustrating how their perspectives were used to inform website
modifications. Content changes included: elaborating on
‘mind-body healing processes’ as participants found this vague
and wanted more information about how placebo effects might
work; adding reassurance that pain is still real even if it reduces
with placebo; adding specific details and evidence from
scientific papers about how many doctors use placebos; and
adding an example to address participants’ concerns about how
doctors can justify using placebos clinically: “For example,
sometimes doctors may listen to a patient's chest, even when it
is not essential for making a medical diagnosis, because it can
be reassuring for the patient.” Stylistic changes included:
choosing photos (for patient’s stories) that look more realistic
as participants felt some looked like stock photos, and thus
lacked authenticity; ensuring alignment and consistent logo
placement throughout as participants noticed minor
misalignments and saw them as unprofessional, reducing the
credibility of the website; and modifying patients’ stories to
always use convincing lay language, and thus avoid the
off-putting impression of advertising. Navigation changes
included: adding a menu bar to all pages to make each page
accessible from any other page, and page buttons changing color
once viewed.
Table 1. Illustrative Quotes from Participants Used to Refine the Website
ModificationQuoteTopic
None neededSo it’s basically asking a question that yes it can help with your pain. And obviously there’s
been quite a big study that shows that it can definitely relieve pain and stiffness. There’s
obviously useful information. (Participant 2)
Content: information on placebo ef-
fects
None neededI think it's good to have a case study. I didn't realize you could do placebo surgeries so
that's quite interesting. (…) It's nice to have a picture of the person as well. It's good to
have the option to read what he says as well, so if you don't want to read it, you can listen
to it. (Participant 3)
Content: patients’ stories
Expand on ‘mind-
body self-healing’
Maybe explain what ‘mind-body self-healing processes’ are. Um otherwise I think like I
understand what it says, yeah. (Participant 1)
Content: technical terms
Add specific de-
tails about how
many doctors use
placebos
What is going through my mind maybe a little bit is maybe kind of if I was to receive the
placebo and not actually know. So maybe something that addresses that, how common it
is to be given a placebo in the health care sector. (Participant 8)
Content: placebos in clinical prac-
tice
Change photosAre these the pictures of the actual people who are talking or are they stock pictures?
(Participant 6)
Style: patients’ stories
Add a side menu
bar that is always
available
Like usual websites have everything on the same page, so it’d have a menu at the side that
you always see. So is a bit confusing because I'm going back, but I cannot remember what
I've clicked on necessarily. It’s all like a flow, you have to go through it, and back again.
I think it might be more useful to have a menu at the edge or something. (Participant 5)
Navigation: menu
The final structure and main content of the website is shown in
Figure 2. Nine topics are covered across 10 main pages (the last
page offering a summary of key facts), which can be accessed
in any order. Text and images are supplemented by scientific
evidence summaries (on 4 pages), audio clips with photos and
transcripts of patients’ experiences (on 4 pages), a film, and 2
quizzes (with immediate feedback). Figure 3 shows one page
(“Can a placebo help with my pain”), annotated with key
features that illustrate the contribution of evidence-, theory-,
and person-based approaches.
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Figure 2. Overview of structure and contents of website.
Figure 3. Example page annotated to highlight key features and their development from evidence-, theory-, and person-based approaches.
Discussion
Summary
We have developed a new website about placebos that conveys
scientifically accurate information in a way that should engage
members of the public and enable them to make informed
choices about placebos. The development process drew on
evidence about placebo effects, theory about education, attitudes
and motivation, and qualitative research to maximize the
website’s likely effects.
Strengths and Limitations
Strengths of this project include the multidisciplinary team and
the combination of evidence-, theory-, and person-based
approaches [28-30]. Team members shared expertise in topics,
including placebo effects, digital interventions, film, and chronic
pain, and contributed diverse professional perspectives (eg,
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psychology, general practice, physiotherapy, acupuncture). Two
team members were patient representatives whose input helped
ensure our website addressed important issues in an accessible
and nonpatronizing manner. By drawing on a combination of
approaches we were able to incorporate evidence, theory, and
users’ perspectives in a flexible manner throughout the
intervention development process.
The main limitation of the study was the homogeneous sample
of participants. Involving a more diverse sample of patients in
our think aloud study would have allowed us to better gauge
the comprehensibility of the website among members of our
target audience, adults with experience of pain symptoms. The
same issues were raised repeatedly across the 10 interviews,
suggesting additional interviews would have produced
diminishing returns for additional cost. However, additional
interviews with people with other characteristics (eg, more
severe chronic pain conditions) might have elicited novel
comments. While participants’ views on the format and structure
of the website were vital for improving its usability, these issues
may have been particularly pertinent for our sample because,
from their comments, they appeared to be experienced Internet
users with a good baseline understanding of placebo effects. A
more diverse sample might have uncovered additional issues
and/or misunderstandings about placebos and placebo effects.
Future think aloud studies for website development would
benefit from sampling diverse participants from the population
of likely end-users and finding ways to encourage them to focus
on the substance of the website as well as its style and structure.
The full person-based approach includes guidance on how to
achieve this to ensure qualitative research goes beyond
user-testing to focus on participants’ perspectives on substantive
issues [30].
Applications
Using our website to inform potential clinical trial participants
about placebos could have both beneficial and detrimental
consequences. For example, it might improve the validity of
informed consent [3], alleviate anxiety about placebos, ease the
process of unblinding to placebo allocation at the end of trials
[15,16], reduce adverse effects [62], and/or enhance recruitment
[14]. However, increasing patients’ expectations of benefit
during trials by encouraging positive beliefs about placebos
might increase the size of the placebo effect [63,64]. This could
introduce bias [65] particularly if placebo and intervention
effects are not additive [66] and/or could reduce estimated
treatment effects [11]. It is therefore vital to test the effects of
providing comprehensive information about placebos before
changing research practice. To contribute to this much-needed
evidence base, we will report separately a randomized
experiment testing the effects of our new website on knowledge
and informed choice about placebos.
Conclusions
In conclusion, we have developed an evidence-based website
that incorporates theory-based techniques to inform members
of the public about placebos and placebo effects. Before using
the website in clinical trials it is necessary to test its effects on
key outcomes, including patients’ knowledge and capacity for
making informed choices about placebos.
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